Inotiv Inc Revenue Growth Rates (NOTV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Inotiv Inc   (NASDAQ: NOTV)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

NOTV's Revenue Growth by Quarter and Year

Inotiv Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NOTV Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter September -
3rd Quarter June -
2nd Quarter March 117.65
1st Quarter December 120.88
FY 238.53

NOTVs Annual Revenue
Inotiv Inc 's Revenue in the fiscal year 2025 $ 513.02 millions
Inotiv Inc 's Revenue in the fiscal year 2024 $ 490.74 millions
Inotiv Inc 's Revenue in the fiscal year 2023 $ 572.43 millions
Inotiv Inc 's Revenue in the fiscal year 2022 $ 547.66 millions
Inotiv Inc 's Revenue in the fiscal year 2021 $ 89.61 millions




NOTV Revenue second quarter 2026 Y/Y Growth Comment
Inotiv Inc reported decrease in Revenue in the second quarter 2026 by -5.36% to $ 117.65 millions, from the same quarter in 2025.
The decrease in the second quarter 2026 Inotiv Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 46.11%.

Looking into second quarter 2026 results within Medical Laboratories industry 21 other companies have achieved higher Revenue growth. While Inotiv Inc ' s Revenue decline of -5.36% ranks overall at the positon no. 2240 in the second quarter 2026.


NOTV Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter September - 5.92 % -7.33 % -6.47 %
3rd Quarter June - 23.53 % -32.82 % -8.8 %
2nd Quarter March -5.36 % 4.44 % -21.4 % 7.95 %
1st Quarter December 0.83 % -11.53 % 10.39 % 45.77 %
FY   - 4.54 % -14.27 % -

Financial Statements
Inotiv Inc 's second quarter 2026 Revenue $ 117.65 millions NOTV's Income Statement
Inotiv Inc 's second quarter 2025 Revenue $ 124.32 millions Quarterly NOTV's Income Statement


NOTV Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter September - 5.71 % 23.28 % -10.62 %
3rd Quarter June - 5.12 % -11.13 % 3.97 %
2nd Quarter March -2.67 % 3.7 % -12.15 % 23.39 %
1st Quarter December -12.49 % -8.08 % -3.72 % -18.42 %
FY (Year on Year)   - 4.54 % -14.27 % -


Back to NOTV Growth rate Comparisons >> Back to NOTV Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #22
Healthcare Sector #324
Overall #2240

Revenue Y/Y Growth Statistics
High Average Low
511.19 % 46.11 % -21.77 %
(Sep 30 2022)   (Sep 30 2013)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #22
Healthcare Sector #324
Overall #2240
Revenue Y/Y Growth Statistics
High Average Low
511.19 % 46.11 % -21.77 %
(Sep 30 2022)   (Sep 30 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Inotiv Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
179.98 % 5.52 % -100 %
(Dec 31 2021)  


NOTV's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Inotiv Inc disclosed fall in Revenue from the first quarter by -2.67% to $ 117.65 millions, from $ 120.88 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Inotiv Inc 's Revenue growth quarter on quarter, overall rank is 2081.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #19
Healthcare Sector #260
Overall #2081
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #19
Healthcare Sector #260
Overall #2081
Revenue Q/Q Growth Statistics
High Average Low
179.98 % 5.52 % -100 %
(Dec 31 2021)  


NOTV's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Inotiv Inc disclosed fall in Revenue from the first quarter by -2.67% to $ 117.65 millions, from $ 120.88 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 18 other companies have achieved higher Revenue quarter on quarter growth. While Inotiv Inc 's Revenue growth quarter on quarter, overall rank is 2081.


Inotiv Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 507.36 $ 514.03 $ 513.02 $ 505.30 $ 480.40
Y / Y Revenue Growth (TTM) 5.61 % 8.19 % 4.54 % 0.85 % -13.09 %
Year on Year Revenue Growth Overall Ranking # 2923 # 430 # 2805 # 2486 # 2173
Seqeuential Revenue Change (TTM) -1.3 % 0.2 % 1.53 % 5.18 % 1.11 %
Seq. Revenue Growth (TTM) Overall Ranking # 2240 # 379 # 2293 # 2435 # 2072


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Inotiv Inc 's cumulative twelve months Revenue were $ 507 millions, company would post below average annual Revenue growth of 1.11% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Inotiv Inc 's Revenue growth from the 120.88% growth in Dec 31 2025.

In the Healthcare sector 396 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 430 to 2923.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 22
Healthcare Sector # 397
Overall # 2923

Revenue TTM Y/Y Growth Statistics
High Average Low
511.19 %
 46.11 %
-21.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 324
S&P 500 # 2240
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2026 period, Inotiv Inc 's cumulative twelve months Revenue were $ 507 millions, company would post below average annual Revenue growth of -21.77% year on year, if the fiscal year would end at Mar 31 2026.
A slow-down in the Inotiv Inc 's Revenue growth from the 120.88% growth in Dec 31 2025.

In the Healthcare sector 396 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 430 to 2923.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 22
Healthcare Sector # 397
Overall # 2923

Revenue TTM Y/Y Growth Statistics
High Average Low
511.19 %
46.11 %
-21.77 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 324
S&P 500 # 2240




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NOTV's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Trisalus Life Sciences Inc -0.03%$ -0.035 millions
Adma Biologics Inc -0.30%$ -0.304 millions
Vaso Corporation-0.54%$ -0.545 millions
60 Degrees Pharmaceuticals Inc -0.92%$ -0.922 millions
Cytosorbents Corporation-0.95%$ -0.945 millions
Conmed Corporation-1.31%$ -1.310 millions
Neuropace Inc -1.32%$ -1.316 millions
Bio techne Corp-1.35%$ -1.353 millions
Schrodinger Inc -1.62%$ -1.619 millions
United Therapeutics Corporation-1.62%$ -1.624 millions
Prokidney Corp -1.74%$ -1.739 millions
Sarepta Therapeutics Inc -1.89%$ -1.887 millions
Fortrea Holdings Inc -2.27%$ -2.272 millions
Ultragenyx Pharmaceutical Inc -2.36%$ -2.363 millions
Teladoc Health Inc -2.47%$ -2.467 millions
Fonar Corporation-2.55%$ -2.551 millions
Puma Biotechnology Inc -2.59%$ -2.593 millions
Coya Therapeutics Inc -2.61%$ -2.612 millions
10x Genomics Inc -2.76%$ -2.763 millions
Plus Therapeutics Inc -2.93%$ -2.927 millions
Infusystem Holdings Inc-2.97%$ -2.973 millions
Solventum Corporation-3.04%$ -3.043 millions
Milestone Scientific Inc -3.15%$ -3.153 millions
Organon and Co -3.50%$ -3.503 millions
Fulgent Genetics Inc -3.89%$ -3.894 millions
Igc Pharma Inc -3.94%$ -3.939 millions
Carlisle Companies Incorporated-3.99%$ -3.988 millions
Harvard Bioscience Inc -4.44%$ -4.437 millions
Castle Biosciences Inc -4.90%$ -4.897 millions
Prestige Consumer Healthcare Inc -4.95%$ -4.953 millions


About Inotiv Inc Revenue Growth Rates (NOTV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Inotiv Inc (CIK 720154).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-033620
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Inotiv Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.